ADHD has been the topic of a number of other reports. Zacks Investment Research raised Alcobra from a sell rating to a hold rating in a report on Tuesday, July 26th. Canaccord Genuity assumed coverage on Alcobra in a report on Tuesday, June 7th. They set a buy rating on the stock. Roth Capital reissued a buy rating and set a $12.00 price target on shares of Alcobra in a report on Tuesday, June 21st. WBB Securities cut Alcobra from a hold rating to a sell rating and decreased their price target for the company from $5.00 to $4.00 in a report on Monday, September 12th. Finally, Barclays PLC assumed coverage on Alcobra in a research report on Monday, August 1st. They set an equal weight rating and a $8.00 price objective for the company. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of $6.47.
Alcobra (NASDAQ:ADHD) opened at 2.65 on Thursday. Alcobra has a 52-week low of $1.95 and a 52-week high of $8.78. The company’s market cap is $73.04 million. The firm’s 50-day moving average price is $4.55 and its 200-day moving average price is $4.49.
Alcobra (NASDAQ:ADHD) last posted its quarterly earnings results on Tuesday, August 30th. The company reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.01. On average, equities analysts anticipate that Alcobra will post ($0.94) EPS for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Fund Advisors raised its position in Alcobra by 1.8% in the second quarter. BlackRock Fund Advisors now owns 361,130 shares of the company’s stock valued at $1,621,000 after buying an additional 6,516 shares in the last quarter. Stifel Financial Corp raised its position in Alcobra by 34.2% in the second quarter. Stifel Financial Corp now owns 62,000 shares of the company’s stock valued at $278,000 after buying an additional 15,800 shares in the last quarter. Palo Alto Investors LLC raised its position in Alcobra by 7.3% in the second quarter. Palo Alto Investors LLC now owns 272,788 shares of the company’s stock valued at $1,225,000 after buying an additional 18,600 shares in the last quarter. Jefferies Group LLC bought a new position in Alcobra during the second quarter valued at approximately $533,000. Finally, VHCP Management LLC raised its position in Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock valued at $2,799,000 after buying an additional 138,813 shares in the last quarter. Institutional investors own 73.69% of the company’s stock.
Alcobra Company Profile
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.